Tuesday, August 08, 2023 10:14:12 PM
Just spit-balling here:
Assuming the company is intentionally leaving us in the dark, wouldn't that go against their fiduciary duties? Let's assume they have already submitted month(s) ago, but the next 10q on Aug 14th states that they are still in the process of finalizing. Wouldn't that be a bit of a smack to the face on investors?
Granted, things could be much further along in the process without submission happening, but this potential information of progress would be beneficial to us as the timeline has dragged on longer than what was anticipated.
I see two scenarios:
1.) (UNLIKLEY): NWBO is farther along than what is currently known. Submission could have happened already. Thermo's and Les's remarks was made to throw off nefarious forces. Acceptance and/or approval is in the works. (Canadian Drug Bank's update back in March may add some small credibility to this theory.)
2.) (LIKLEY): NWBO has not yet submitted. Les's talk on the Big Show and Thermo's comments hold merit on filings being finalized still, and the Canadian Drug Bank's update was just a routine manner for anticipated drugs coming out of Phase 3 trails that may or may not get regulatory approval (my assumption).
Hoping we are all surprised with approval news (or something in between), but IMO, it's looking as if we are still waiting on submission. Aug 14th's 10q will tell us more hopefully.
Assuming the company is intentionally leaving us in the dark, wouldn't that go against their fiduciary duties? Let's assume they have already submitted month(s) ago, but the next 10q on Aug 14th states that they are still in the process of finalizing. Wouldn't that be a bit of a smack to the face on investors?
Granted, things could be much further along in the process without submission happening, but this potential information of progress would be beneficial to us as the timeline has dragged on longer than what was anticipated.
I see two scenarios:
1.) (UNLIKLEY): NWBO is farther along than what is currently known. Submission could have happened already. Thermo's and Les's remarks was made to throw off nefarious forces. Acceptance and/or approval is in the works. (Canadian Drug Bank's update back in March may add some small credibility to this theory.)
2.) (LIKLEY): NWBO has not yet submitted. Les's talk on the Big Show and Thermo's comments hold merit on filings being finalized still, and the Canadian Drug Bank's update was just a routine manner for anticipated drugs coming out of Phase 3 trails that may or may not get regulatory approval (my assumption).
Hoping we are all surprised with approval news (or something in between), but IMO, it's looking as if we are still waiting on submission. Aug 14th's 10q will tell us more hopefully.
Bullish
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
